- Notice to attend the Extra General Meeting of Olink Holding AB (publ)
- Olink® Target 48 Immune Surveillance Panel – The Next Frontier in Immune Biomarker Profiling with Absolute Confidence
- Researchers Use Olink® Explore to Identify Circulating Proteins That May Give Cancer Warning 7 Years Before Diagnosis
- Olink reports first quarter 2024 financial results
- Report from the Annual General Meeting of Olink Holding AB (publ) on 19 April 2024
- Olink® Insight Unveils Open-access Map of the Human Proteome, Aiding Biomarker Discovery and Understanding of Disease
- Olink reports fourth quarter and full year 2023 financial results
- Olink publishes 2023 annual report
- Notice to attend the Annual General Meeting of Olink Holding AB (publ)
- Olink announces change of date for Annual General Meeting
More ▼
Key statistics
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 124.74m |
Free float | 41.90m |
P/E (TTM) | -- |
Market cap | 3.21bn USD |
EPS (TTM) | -0.2704 USD |
--
More ▼